SCHEMBL13633638

SCHEMBL13633638

CC(Cc1ccc(-c2ccnc(NC3CC(C)(C)NC(C)(C)C3)n2)cc1)N=[N+]=[N-]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 10/20 0.43
MAPK8 P45983 2/20 0.36
CDK2 P24941 4/20 0.35
CCNA2 P20248 3/20 0.35
CDK1 P06493 2/20 0.35
CDK4 P11802 2/20 0.35
CCNB1 P14635 2/20 0.35
CCND1 P24385 2/20 0.35
CCNA1 P78396 2/20 0.35
ROCK2 O75116 3/20 0.34
KCNH2 Q12809 1/20 0.34
CLK1 P49759 1/20 0.33
CLK2 P49760 1/20 0.33
DYRK1A Q13627 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
CCNE1 P24864 1/20 0.33
CCND3 P30281 1/20 0.33
CDK6 Q00534 1/20 0.33
MAPK9 P45984 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633601 0.91 IKBKB (0.39) IKBKBMAPK8CDK2CCNA2CDK1
SCHEMBL16200020 0.87 IKBKB (0.43) IKBKBMAPK8CDK2CCNA2CDK1
SCHEMBL4489766 0.84 IKBKB (0.45) IKBKBMAPK8CDK2CCNA2CDK1
SCHEMBL3477899 0.84 IKBKB (0.45) IKBKBMAPK8CDK2CCNA2CDK1
SCHEMBL3477574 0.79 IKBKB (0.41) IKBKBMAPK8CDK2CCNA2CDK1
SCHEMBL3472713 0.79 IKBKB (0.41) IKBKBMAPK8CDK2CCNA2CDK1
SCHEMBL3478250 0.78 IKBKB (0.45) IKBKBMAPK8ROCK2KCNH2MAPK9
SCHEMBL3471613 0.77 IKBKB (0.49) IKBKBMAPK8CDK2CCNA2CDK1
SCHEMBL4477031 0.77 IKBKB (0.40) IKBKBMAPK8CDK2CCNA2CDK1
SCHEMBL4482129 0.77 SYK (0.46) IKBKBMAPK8ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK IKBKB 2/4885MAPK8 197/4885CDK2 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.